Tiny Lungs, Big Challenge: The Treatment Landscape of Pediatric Tuberculosis
Pulmonary Medicine · 2026-01 · 2026 (1)
DOI: 10.1155/pm/9686798 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pulmonary Medicine, online erschienen am 28.10.2026. Verfasst von Lucia N Dumeni und 2 weiteren Autor:innen. Beteiligte Einrichtung: Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Scienc…. Hauptthemen laut MEDLINE: Antitubercular Agents, Tuberculosis, Tuberculosis, Pulmonary. Die Arbeit nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation.
Abstract (Originalsprache)
Tuberculosis was a lethal disease until the early 1950s, when the first anti‐TB drugs were discovered. These drugs saved many lives until bacteria developed resistance in the 1980s. As a result, TB has re‐emerged as a global health challenge, affecting both drug‐susceptible and drug‐resistant cases. Although tuberculosis is a preventable and curable disease, it remains a major global health burden for both adults and children. High‐prevalence cases in children threaten eradication efforts because they can become fatal in the future. The review is aimed at compiling knowledge on pediatric TB treatment, particularly oral formulations. Efforts have been made over the years to improve pediatric TB treatment. Challenges remain in gathering pharmacokinetic data for children, distributing child‐friendly formulations worldwide, and strengthening collaboration among stakeholders. These issues affect clinical outcomes and hinder the eradication of this infection. Currently, there is a global initiative to improve access to high‐quality TB medications and to utilize new technology, such as developing nanoformulations and dispersible tablets, for better drug delivery. Continued progress, innovation, and fostering partnerships are necessary to overcome existing challenges in TB treatment and to develop child‐friendly formulations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, wits.…
- Infectious Diseases and Oncology Research Institute (IDORI), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, wits.ac.za.
ORCID-Profile: Lucia N Dumeni, Pradeep Kumar, Yahya E Choonara
Förderung
- National Research Foundation
Zitieren
APA
Dumeni, L. N., Kumar, P., & Choonara, Y. E. (2026). Tiny Lungs, Big Challenge: The Treatment Landscape of Pediatric Tuberculosis. Pulmonary Medicine, 2026(1). https://doi.org/10.1155/pm/9686798
Vancouver
Dumeni LN, Kumar P, Choonara YE. Tiny Lungs, Big Challenge: The Treatment Landscape of Pediatric Tuberculosis. Pulmonary Medicine. 2026;2026(1). doi:10.1155/pm/9686798
BibTeX
@article{Dumeni2026,
author = {Dumeni, Lucia N and Kumar, Pradeep and Choonara, Yahya E},
title = {Tiny Lungs, Big Challenge: The Treatment Landscape of Pediatric Tuberculosis},
journal = {Pulmonary Medicine},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/pm/9686798}
}
EUVIMED